Advanced Medical Solutions Group Regulatory News (AMS)

17 December 2013

Advanced Medical Solutions Group plc

("AMS" or the "Group")

Pre-Close Trading Update

Winsford, UK: Advanced Medical Solutions Group plc(AIM: AMS.L), the global medical technology company, today announces an update on trading prior to its close period for the year ending 31 December 2013.

The good progress made by the Group, as highlighted in the 2013 Interim Results announcement on 11 September 2013, has continued into the second half of the year with growth continuing from silver alginate and the Group's ActivHeal®, LiquiBand®and RESORBA®ranges. The Group is also pleased to report that it has repaid its term loan and will be debt free at the end of 2013.

The Board confirms that it expects both revenue and profitability for the full year 2013 to be in line with current market expectations.

Dr. Don Evans, Chairman of AMS, said:

"As previously advised, I will leave the Board in two weeks time after 16 years at AMS and I would like to thank all the people who I have worked with during this time for their invaluable contributions to building the successful, multinational business that AMS now is. I am delighted that the Group continues to make such good progress and I am confident that this will continue under the experienced guidance of my successor, Peter Allen."

- ends -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com 

Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$15 billion global wound care market. Through a mix of organic development and a number of acquisitions, AMS now has a wide range of products based on technologies that include alginates, silver alginates, foams, collagens, cyanoacrylate adhesives and sutures.

AMS manufactures wound care products for an extensive list of Original Equipment Manufacturer ("OEM") customers around the world, but the majority of the Group's revenues now come from its own brands - ActivHeal® wound care products in the UK to the NHS, LiquiBand® cyanoacrylate products primarily in the UK, Europe and the USA, and RESORBA® sutures and collagen wound care products primarily in Europe. AMS develops innovative products from its R&D pipeline which it commercialises globally, either directly or through partnerships with its OEM customers.

AMS's products are sold globally via a network of regional or multinational partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia.

With 450 employees operating under four distinct business units (Branded Direct, Branded Distributed, OEM and Bulk Materials) that match its multiple products and routes-to-market, AMS's products are manufactured from two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic.